Genscript Biotech Corporation (GNNSF)
| Previous close | 1.4000 |
| Open | 1.4700 |
| Bid | 1.0300 x 40000 |
| Ask | 1.1600 x 0 |
| Day's range | 1.4000 - 1.4700 |
| 52-week range | 1.0500 - 3.2000 |
| Volume | |
| Avg. volume | 13,026 |
| Market cap | 3.053B |
| Beta (5Y monthly) | 1.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 June 2017 |
| 1y target est | N/A |
- PR Newswire
GenScript Hosts Inaugural APAC Distributor Meeting, Strengthening Regional Partnerships for Scientific Advancements
GenScript, the world-leading biotechnology company specializing in life science research and applications, hosted the inaugural Asia-Pacific (APAC) Distributor Meeting in Nanjing, China. The event, which took place from 3rd to 6th June, brought together distributors from across the APAC region to discuss strategies, share insights, and strengthen collaborations to better serve the scientific community.
- PR Newswire
GenScript Biotech Corporation Launches FLASH Gene Service: The Fastest and Most Affordable Gene Synthesis Solution on the Market
GenScript Biotech Corporation, renowned for its relentless innovation in synthetic biology and industry-leading gene synthesis services, is excited to announce the launch of its newest offering, GenScript FLASH Gene service, the ultra-fast sequence-to-plasmid (S2P) service. This flagship offering addresses the urgent demand for delivering gene constructs with unmatched speed, quality, and cost-efficiency.
- PR Newswire
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications
GenScript Biotech Corporation, a global leader in life science research tools and services, has today announced the expansion of its in vitro transcription (IVT) RNA synthesis portfolio to include self-amplifying RNA (saRNA). This cutting-edge addition reinforces GenScript's position at the forefront of IVT RNA technology, offering a new and novel format for researchers working in applications such as vaccine, cancer immunotherapy, and gene or cell therapy development.
